Core Viewpoint - The announcement by Tibet Pharmaceutical indicates that its subsidiary, Chengdu Nodi Kang Biopharmaceutical Co., Ltd., has its product, recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan), included in the National Medical Insurance Directory for 2025 and adjusted to the regular directory [1] Group 1 - The product will continue to be covered by the national medical insurance, which is a significant advantage for the company [1] - The adjustment to the regular directory may enhance the product's market accessibility and potential sales [1]

Group 1 - The core product, recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan), has been included in the National Medical Insurance Directory and adjusted to the regular category, effective January 1, 2026 [1][4] - Xinhuasuan is a first-class new biological product developed by the company, used for treating acute heart failure, improving symptoms and quality of life for patients, while also reducing hospitalization costs and duration [1][2] - The product's production and sales figures indicate strong performance, with 7.35 million units produced and 7.01 million units sold in 2024, generating revenue of 2.433 billion yuan, accounting for 86.89% of the company's main business income [3] Group 2 - The adjustment to the regular category is expected to have a positive impact on the company's future product sales and long-term development, although the specific impact on operating performance cannot yet be estimated [4]

Core Viewpoint - Tibet Pharmaceutical (600211) has seen a positive market response following the announcement that its subsidiary's product, Xinhuasuan, has been included in the National Medical Insurance Drug List for 2025, which is expected to enhance future sales and operational development [1][2]. Group 1: Company Performance - As of December 8, 2025, Tibet Pharmaceutical's stock closed at 41.97 CNY, up 0.65% from the previous trading day, with a total market capitalization of 13.528 billion CNY [1]. - The stock opened at 41.78 CNY, reached a high of 42.19 CNY, and recorded a low of 41.78 CNY, with a trading volume of 96.8223 million CNY and a turnover rate of 0.71% [1]. Group 2: Product and Market Impact - The product Xinhuasuan, a recombinant human brain natriuretic peptide injection, is primarily used for the short-term treatment of acute decompensated heart failure and is limited to use in secondary and higher medical institutions [1]. - In 2024, Xinhuasuan is projected to generate sales revenue of 2.433 billion CNY, accounting for 86.89% of the company's main business revenue; in the first half of 2025, it is expected to generate 1.456 billion CNY, representing 88.36% of the revenue [1]. - The inclusion of Xinhuasuan in the regular drug list is anticipated to have a positive impact on the company's future sales and operational growth [1].

具体至产品本身，公告介绍，新活素是公司自主研发的国家生物制品一类新药，作为治疗急性心衰的基 因工程药物，能快速改善心衰患者的心衰症状和体征，提高患者的生存质量，并降低患者的心衰住院治 疗费用和缩短住院时间。同时，该药品技术指标国际领先，对公司在基因工程药物领域研发、生产具有 较强指导意义。 依托良好的临床价值，新活素不仅得到市场的广泛认可，也成为公司的业绩支柱。公告指出，该产品 2024年销售量达700.83万支，销售收入24.33亿元；2025年上半年销售量416.72万支，销售收入14.56亿 元。据悉，相较庞大的心衰市场，目前新活素渗透率并不高，后续仍有较大的增长空间。而转入常规目 录后，更稳定的价格，也将进一步强化公司长期业绩增长的预期。 12月8日，西藏药业（600211）(600211.SH)披露一则关于公司产品新活素被继续纳入国家医保药品目录 的公告。据12月7日国家医保局及人力资源和社会保障部发布的《国家基本医疗保险、生育保险和工伤 保险药品目录(2025年)》，公司全资子公司成都诺迪康生物制药有限公司生产的注射用重组人脑利钠肽 (商品名：新活素)持续被纳入医保目录，并由此前协议期内谈判药品部 ...

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

公告显示，新活素为国家生物制品一类新药，适用于患有休息或轻微活动时呼吸困难的急性失代偿心力 衰竭患者的静脉治疗。作为治疗急性心衰的基因工程药物，能快速改善心衰患者的心衰症状和体征，提 高患者的生存质量，并降低患者的心衰住院治疗费用和缩短住院时间。 北京商报讯（记者 王寅浩 宋雨盈）12月8日，西藏药业发布公告称，公司全资子公司成都诺迪康生物制 药有限公司生产的注射用重组人脑利钠肽（商品名：新活素）持续被纳入医保目录，并被调整至常规目 录。 ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-043 西藏诺迪康药业股份有限公司 关于公司产品新活素被继续纳入国家医保药品目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 12 月 7 日，国家医保局、人力资源社会保障部发布了《国家基本医疗保险、 生育保险和工伤保险药品目录（2025 年）》，我公司全资子公司成都诺迪康生物制药有限 公司生产的注射用重组人脑利钠肽（商品名：新活素）持续被纳入医保目录，并被调整至 常规目录，具体情况如下： | 药品分类代码 | 药品分类 | 编号 | 药品名称 | 备注 | | --- | --- | --- | --- | --- | | XC01E | 其 他 心 脏 疾 | 368 | 注 射 用 重 组 | 限二级及以上医疗机构用于 | | | 病用药（乙） | | 人脑利钠肽 | 规范治疗效果不佳的急性失 | | | | | | 代偿性心力衰竭短期治疗。 | | | | | | 住院方可支付，单次支付不 | | | | | | 超过 3 天。 | ...

新活素系我公司自主研发的国家生物制品一类新药，作为治疗急性心衰的基因工程药物，能快速改善心 衰患者的心衰症状和体征，提高患者的生存质量，并降低患者的心衰住院治疗费用和缩短住院时间。同 时，该药品技术指标国际领先，对公司在基因工程药物领域研发、生产具有较强指导意义。 格隆汇12月8日丨西藏药业(600211.SH)公布，2025年12月7日，国家医保局、人力资源社会保障部发布 了《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，我公司全资子公司成都诺迪康生 物制药有限公司生产的注射用重组人脑利钠肽（商品名：新活素）持续被纳入医保目录，并被调整至常 规目录。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

证券简称：西藏药业 证券代码：600211 编号：2025-042 西藏诺迪康药业股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于 2025 年 12 月 3 日（星期三）15:00-16:00 在上海证券交易所上证路演中 心（网址：http://roadshow.sseinfo.com/），以网络文字互动方式召开了公司 2025 年 第三季度业绩说明会，现将召开情况公告如下： 一、业绩说明会召开情况 1、公司三季报业绩公布后，社保基金三季度清仓，公司股价全面下挫，是什么原因？ 公司拳头产品新活素在三季度销量为何同比减少？预计全年业绩会怎样？今年的政府补 贴还有吗？公司近期的两笔对外投资（江苏晨泰和锐正基因），预计何时会有成效，风险 防控方面有哪些措施？ 机构持仓变化是基于其自身投资决策等多重因素而进行的市场行为。公司股价小幅 下降，估计是受行业情况、市场波动等多重因素影响。 截止目前，公司基本面未发生较大变化，第三季度新活素销量减少主要受销售波动 影响 ...